Several groups have provided evidence that posi tron emission tomography (PET) and single-photon emission computed tomography (SPECT) neuroreceptor imaging tech niques might be applied to measure acute t1uctuations in do pamine (OA) synaptic concentration in the living human brain. Competition between OA and radioligands for binding to O2 receptor is the principle underlying this approach. This new application of neuroreceptor imaging provides a dynamic mea surement of neurotransmission that is likely to be informative to our understanding of neuropsychiatric conditions. This ar ticle reviews and discusses the body of data supporting the feasibility and potential of this imaging paradigm. Endogenous competition studies performed in rodents, nonhuman primates, and humans are first summarized. After this overview, the va lidity of the model underlying the interpretation of these im aging data is critically assessed. The current reference model is defined as the occupancy model, since changes in radiotracer binding potential (BP) are assumed to be directly caused by changes in occupancy of O2 receptors by OA. Experimental data supporting this model are presented. The evidence that manipulation of OA synaptic levels induces change in the BP of several O2 radiotracers (catecholamines and benzamides) is unequivocal. The fact that these changes in BP are mediated by changes in OA synaptic concentration is well documented. The relationship between the magnitude of BP changes measured with PET or SPECT and the magnitude of changes in OA concentration measured by microdialysis supports the use of these noninvasive techniques to measure changes in neuro transmission. On the other hand, several observations remain unexplained. First, the amphetamine-induced changes in the BP of O2 receptor antagonists [1 2 3IJIBZM and [I I Clraclopride last longer than amphetamine-induced changes in OA extracellular concentration. Second, nonbenzamide O2 receptor antagonists, such as spiperone and pimozide, are not affected by changes in OA release, or are affected in a direction opposite to that pre dicted by the occupancy model. Similar observations are re ported with 0 I radiotracers. These results suggest that the changes in BP following changes in OA concentration might not be fully accounted by a simple occupancy model. Specifi cally, the data are reviewed supporting that agonist-mediated receptor internalization might play an important role in char acterizing receptor-ligand interactions. Finally, it is proposed that a better understanding of the mechanism underlying the effects observed with benzamides is essential to develop this imaging technique to other receptor systems.
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Over the last decade, numerous studies have provided data suggesting that, under specific conditions, in vivo neuroreceptor imaging with positron emission tomogra phy (PET) and single-photon emission computed tomog raphy (SPECT) could be used to measure acute fluctua tions in synaptic concentration of neurotransmitters. Competition between endogenous transmitters and radio ligands for binding to neuroreceptors is the principle un derlying this technique: changes in transmitter synaptic concentration translate in changes in transmitter receptor occupancy that can be detected as changes in the binding potential (BP) of the radioligand. This promising new application of neuroreceptor imaging has the potential to enable direct measurement of synaptic transmission in the living brain and correlations of these dynamic mea surements with behaviors and symptoms. This idea has been applied mostly to the measurements of changes in dopamine (DA) concentration in the milieu surrounding DA D2 receptors.
The idea to apply competition techniques and PET to the assessment of DA synaptic level was proposed as early as 1984 (Friedman et aI., 1984) . Nonetheless, en dogenous competition studies became a major focus of PET and SPECT research only during the last decade. A possible reason for this delay is that during the late 1970s and most of the 1980s, the butyrophenone [ 3 H] spiperone or its methylated analog [ II CJN-methy1-spiperone ([ II C]NMSP) were the most widely used radioligands to label D2 receptors in vivo (Leysen et aI., 1978; Wagner et aI., 1983; Lyon et aI., 1986) . Studies performed with these ligands did not support the feasibility of this ap plication. The development of substituted benzamides such as [ 11 C]raclopride and [ 1 2 3 IJIBZM as imaging agents (Ehrin et aI., 1985; Kohler et aI., 1985; Kung et aI., 1988a,b) was essential in transforming this theoreti cal idea into a valuable research tool. The development of the endogenous competition con cept in the brain imaging field also is linked to the con troversies and debates that followed publications of dis crepant results regarding the density of D2 receptors in schizophrenia. Using [ II C]NMSP, Wong et al. (1986b) reported a large increase in the density of D2 receptors in patients with schizophrenia; while using [ 11 C]raclopride, Farde et al. (1990) reported no change. In two noted communications, Seeman et al. (1988 Seeman et al. ( , 1989 argue that this discrepancy might arise from a different "sensitiv ity" of [ 1l C]raclopride and [ " C]NMSP binding to en dogenous competition by DA. This hypothesis played an important role in bringing the endogenous competition concept to the attention of the imaging field. This interest translated in numerous investigations that characterized in detail the phenomenon of endogenous competition between DA and various D2 receptor radio tracers. The use of this technique to measure DA trans mission has been extensively validated and was success- Vol. 20, No. 3, 2000 fully applied to characterize alterations of DA transmis sion in clinical conditions. On the other hand, application of the same principle to other transmission systems has not substantially emerged, The difficulties encountered in extending this idea to other receptor systems call for a critical examination of the data obtained with D2 recep tors, This line of research has emerged under a theoretical framework referred to here as the occupancy model (Fig.  I) . This model predicts that challenges that increase DA synaptic concentration will result in increased occupancy of D2 receptors by DA, and reduced availability of D2 receptors for binding of the radiotracer. On the other hand, manipulations that decrease DA synaptic concen tration will reduce D2 receptor occupancy by DA and increase D2 receptor availability to radiotracer binding. This article first reviews studies in rodents, nonhuman primates, and humans that evaluated in vivo competition between DA and radiolabeled D2 and D I receptor li gands. After presenting these data, this report addresses several issues pertinent to the validity of the theoretical framework (i.e., the occupancy model) supporting the interpretation of these results. Results incongruent with the occupancy model receive special attention. This ar ticle concludes by examining the limitations of the oc cupancy model and speCUlating about other mechanisms that might be involved in altering radioligand binding after acute fluctuations of synaptic neurotransmitter levels. Schematic representation of the classic occupancy model adopted to explain the increase and decrease of ["C]ra clop ride binding following depletion or stimulation, respectively, of dopamine concentration in the vicinity of D 2 receptors, This model postulates that changes in [1 1 C] raclopride binding poten tial are directly related to the changes in occupancy of D 2 recep tors by dopamine, The figure is misleading inasmuch as r"C]ra clopride, at tracer dose, occupies only a fraction of the available receptors. The effective binding of C 1 C]raclopride is related to the binding potential, which in turn is affected by the presence of dopamine in a complex manner, since dopamine affects both the number and affinity of available sites.
LITERATURE REVIEW
A variety of O2 and 0 1 receptor radioligands have been used in experiments evaluating the impact of ma nipulation of synaptic OA on radio ligand binding in vivo. O2 receptor radioligands include the agonists propyl norapomorphine (NPA) and apomorphine (APO), and a variety of antagonists including raclopride, IBZM, IBF, fallypride, spiperone, N-methyl-spiperone (NMSP), and pimozide. 0 1 receptor radio ligands include the agonist SKF 82957 and the antagonists SCH 23390, NNC 756, and NNC 112. Table 1 lists the affinity and lipophilicity of these agents. A representative value of Kd or logP was chosen when several values were available in the litera ture. For logP, values determined by the octanol-water partitioning method (shake-flask method) were selected when available. Table 1 also lists the vulnerability of these tracers to endogenous OA competition, as derived from the litera ture review detailed later. Inspection of Table 1 rapidly reveals that neither pharmacologic effect (agonist versus antagonist), affinity, or lipophilicity are appropriate pre dictors of vulnerability to endogenous OA competition. Rather, this property appears to be associated to the chemical class. The in vivo binding of catecholamines (NPA and APO) and benzamides (raclopride, IBZM, IBF, fallypride) is affected by endogenous OA in a man ner consistent with the occupancy model, whereas other radiotracers (butyrophenones, benzazepines) show either no change or change in the direction opposite to predic tions of the occupancy model. Table 2 lists in vivo studies in rodents (rats and mice) that measured changes in the accumulation of a variety of DA receptor radioligands after pharmacologic chal lenges or other manipulations expected to decrease or increase synaptic DA concentration. Studies are sorted by receptor systems, radioligands, and type of challenge (expected effect of the challenge on DA synaptic con centration, i.e., inhibition or augmentation of synaptic DA). For each study, Table 2 lists the observed effect of the challenge on radioligand binding (increase, decrease, no change), the consistency of the results with the simple occupancy model (yes, no, or paradoxical) , and the ref erence. Challenges aimed at depleting or inhibiting DA synaptic concentration include pharmacologic adminis tration of the vesicle-depleting agent reserpine, the neu ronal impulse flow inhibitor -y-butyrolactone, and the ty rosine hydroxylase inhibitor alpha-methyl-para-tyrosine (AMPT), as well as chemical destruction of DA neurons with 6-0H-dopamine. Inhibition of OA release also was indirectly achieved by increasing GABAergic transmis sion (flunitrazepam, NNC 711). Direct augmentation of DA synaptic concentration was achieved with the OA releaser amphetamine, inhibitors of dopamine transport ers (OAT) including methylphenidate, cocaine, bupro prion, amfonelic acid, nomifensine, GBR 12909, and the DA precursor L-DOPA. Stimulation of DA transmission was also indirectly induced by the N-methyl-D-aspartate (NMDA) antagonist MK801.
Studies in rodents
The model referred to here as the occupancy model (increase in DA synaptic levels results in decrease in tracer accumulation, and vice versa) is fully supported by data obtained with eH]NPA, [ 11 C]APO, [ 3 H]raclopride, or [ 1 2 3 I]IBZM. In contrast, data obtained with eHlspi perone and eH]pimozide do not support this model. In fact, most of the results obtained in rodents with these two radioligands indicate regulations in the direction op posite to predictions of the occupancy model: inhibition of DA release resulted in paradoxical decrease in radio ligand-specific binding, whereas stimulation of DA re lease resulted in paradoxical increase in radioligand specific binding.
Most rodent studies published during the 1970s and 1980s were performed with these "paradoxical" radio tracers (spiperone and pimozide). In 1988, the only data (Kobayashi and Inoue, 1993) available to support the occupancy model were the stud ies of van der Werf et al. (1983) and Kohler et al. (1981) that the paradoxical behavior of eH]spiperone uptake agonist challenge resulted from agonist-promoted recep tor internalization, a phenomenon resulting in an effec tive "trapping" of l 3 H]spiperone in the cells.
The following year was a turning point with the pub lication of the elegant and influential studies by Ross and Jackson (l989a, J989b logic challenges under comparable and carefully con trolled conditions, and definitively established the differ ences in the behavior of these radio tracers vis-a-vis DA synaptic concentration. Opposite effects also were ob served after indirect challenges. Gamma-aminobutyric acid agonists that are expected to inhibit DA release were shown to decrease eH]spiperone binding (Nakano et aI., 1998) , but to increase [ I I C]raclopride binding (Dewey et aI., 1992) . The NMDA antagonists (ketamine and MK-80l) increased [ " C]NMSP binding (Onoe et aI., 1994) but decreased [ ' I C]raclopride binding (Breier et aI ., 1998; Ginovart et aI., 1998; Smith et aI., 1998) . Interestingly, D I receptor radiotracers, whether ago nists or antagonists, behave more like spiperone than raclopride. The uptake of the D I receptor agonist [ II C]SKF 82957 was not affected by reserpine or am phetamine (Greenwald et aI., 1998) . For the antagonist eH]SCH 23390, inhibition of DA release with reserpine (Inoue et aI., 1991) or tlunitrazepam (Inoue et aI., 1992) induced decreased radiotracer accumulation, whereas stimulation of DA release with MK-801 induced in creased accumulation (Kobayashi and Inoue, 1993) . Thus, like spiperone and its analog, D I receptor radio tracers appear to show either no change or paradoxical response to acute DA manipulations.
Studies in nonhuman primates
Studies performed with PET and SPECT in nonhuman primates are listed in Table 3 . The first two articles re porting DA-ligand interactions with PET were per formed with [ 18 F]NMSP (Dewey et aI., 1990; Logan et aI., 1991) and report results consistent with the occu pancy model (but inconsistent with the rodent studies reviewed earlier). In 1990, Dewey et al. (1990) reported that the anticholinergic and DA uptake inhibitor drug benztropine reduced the striatal uptake of [ 18 F]NMSP in the baboon brain. The following year, the same group reported that amphetamine also reduced [ 18 F]NMSP striatal uptake in the baboon brain (Dewey et aI., 1991) . This report was followed by a more comprehensive ki netic analysis of the same data by Logan et al. (1991) .
Starting in 1992, several of studies in primates have reported the effect of direct DA enhancing challenges on [ " C]raclopride in baboon: [ ' ' C]raclopride BP was con sistently shown to be reduced by amphetamine, GBR 12909, cocaine, methylphenidate, and electrical stimula tion of dopaminergic neurons (Villemagne et aI., 1988; Dewey et aI., 1993; Carson et aI., 1997; Hartvig et aI., 1997; Ginovart et aI., 1998; Price et aI., 1998; Abi Dargham et aI ., 1999; Ginovart et aI., 1999; Volkow et aI ., 1999) . Direct depletion of endogenous DA by reser pine or gamma-hydroxybutyrate increased [ 11 C]raclo pride BP (Gatley et aI ., 1995b; Ginovart et aI., 1997) . r II C]Raclopride BP was sensitive to indirect manipula tion of DA transmission, and these interactions were con sistent in their directionality with the occupancy model. Challenges expected to decrease DA release (by increas ing gamma-aminobutyric acid and 5-hydroxytryptamine [5-HT] transmission) resulted in increased [ 11 C]raclo pride binding (Dewey et aI., 1992; Dewey et aI., 1995) , whereas the NMDA antagonist ketamine, a drug ex pected to increase DA transmission, decreased [ ll C]ra clopride binding (Ginovart et aI., 1998) . Studies in primates with the raclopride analog [ 1 2 3 I]IBZM report similar interactions. Augmentation and inhibition of DA release were reported to decrease and increase, respectively, the specific binding of [ In ljIBZM in baboons (Innis et aI., 1992; Laruelle et aI., 1997b) . Several other benzamides, such as [ 1 2 3 IjIBF, [ ,s F]FCP, and [ 18 P]fallypride, also were shown to be affected by endogenous DA augmentation (Kessler et aI., 1993; Laruelle et aI., 1997b; Mach et aI., 1997; Mukher jee et aI., 1997; Price et aI., 1998) .
Although the first studies published in baboons were performed with [ 18 p]NMSP and reported positive results, a recent study compared, in the same laboratory, the effects of amphetamine on [ II C]NMSP and [ ' l C]raclo pride binding in primates (Hartvig et aI., 1997) . This article reported the usual effect of amphetamine on [ II C]raclopride binding but failed to detect an amphet amine effect on [' I C]NMSP binding. In the same con text, the study that reported a paradoxical increase in r " C]NMSP accumulation after ketamine is noticeable (Onoe et aI., 1994) , especially in light of the opposite effect of ketamine on [ 11 C]raclopride (Ginovart et aI., 1998) . Thus, the lack of effect, or the presence of a paradoxical effect of DA release reported in the rodent literature, is supported by some (Onoe et aI., 1994;  Hartvig et aI.. 1997) but not all (Dewey et aI., 1990; Logan et aI., 1991) PET studies in baboons.
Finally, studies performed in baboons with several D I radiotracers failed to detect an effect of amphetamine on e1ClSKF 82957. e1ClSCH 23390. and [ ll ClNNC 756 (Laruelle et aI., 1998; Abi-Dargham et aI., 1999; Chou et aI., 1999) .
Studies in healthy humans
Since primates studies clearly established a robust ef fect of endogenous DA manipulation on e 1 Clraclopride and e 23 I]IBZM BP, it is not surprising that these radio- (Chou et aI., 1999) tracers were selected to evaluate the existence of such interactions in humans ( Table 4 ). The first literature report of an endogenous competi tion study in humans is buried in the discussion of an article examining occupancy of D 2 receptors with anti psychotic drugs (Farde et aI., 1992) . An oral dose of 30 mg of amphetamine was reported to decrease [ ll Clraclo pride BP by an average of 10% in three healthy volun teers. The first comprehensive report of this effect in humans was published by Volkow et aI. (1994) . Meth ylphenidate given intravenously (0.5 mg/kg) reduced [ ll Clraclopride BP by an average of 23%. This article (Laruelle et aI., 1995) . Amphetamine (0.3 mg/kg intravenously) de creased [ 1 23 1]IBZM BP by 15%. Both studies revealed relationships between the magnitude of DA release as assessed by the radiotracer displacement and the subjec tive states reported by the subjects, either before (Volkow et aI., 1994) or after (Laruelle et aI., 1995) the psychostimulant challenge. The vulnerabilities of [ II C]raclopride and C 2 3 1]IBZM to psycho stimulant challenges in humans were indepen dently confirmed with amphetamine, which induced a 16% decrease in [ 11 C]raclopride BP (Breier et aI., 1997) , and methylphenidate, which induced a 8% decrease of C 2 3 I]IBZM (Booij et aI., 1997) .
Test-retest studies demonstrate that the amphetamine induced decrease in C 2 3 I]IBZM BP could be measured with high reliability in humans (Kegeles et aI., 1999) . The methylphenidate-induced decrease in C l C]raclo pride BP was less reproducible (intraclass correlation coefficient of 0.58, Wang et aI., 1999) than the amphet amine-induced decrease in [ 1 23 1]IBZM BP (intraclass correlation coefficient of 0.89, Kegeles et aI., 1999) , maybe because the effect of methylphenidate on DA re lease is more affected by the subjective environment and experience compared with the amphetamine effect.
Cocaine (48 mg) also was reported to affect C l C]ra clopride uptake (1 1 % decrease) in chronic cocaine abus ers (Schlaepfer et aI., 1997) . The NMDA antagonist ke tamine decreased [ 1 l C]raclopride BP by 13% (Smith et aI., 1998) and 10% (Breier et aI., 1998) . The hallucino gen psilocybin, a potent 5HT 2 A agonist, decreased [ 11 C]raclopride BP by 20% (Vollenweider et aI., 1999) .
Decrease
Yes ( Yes (Kegeles et aI., 1999) Video game playing was showed to be associated with a decrease in C 1 C]raclopride BP (13%), similar in magni tude to the decreases BP induced by amphetamine (0.5 mg/kg intravenously) and cocaine (48 mg intravenously) (Koepp et aI., 1998) .
Finally, DA depletion studies in humans showed that acute AMPT challenge resulted in 29% increase in [ 1 23 1]IBZM BP (Laruelle et aI., 1997a) .
Clinical studies
Five clinical studies compared the effects of stimula tion of DA release on in vivo binding of [ 11 C]raclopride and [ 1 23 I]IBZM in controls and patients with psychiatric conditions (Table 5 ). Using [ 1 23 I]IBZM, Laruelle et al. (1996) and Abi-Dargham et al. (1998) report increased amphetamine-induced (0.3 mg/kg) DA release in patients with schizophrenia compared with matched healthy con trols. In patients with schizophrenia, the magnitude of amphetamine-induced DA release estimated by the dis placement of [ 1 23 I]IBZM was related to a transient in crease in positive symptoms. A similar result was pub lished by Breier et al. (1997) using C l C]raclopride and a lower dose of amphetamine (0.2 mg/kg). This result also was observed in patients experiencing a first episode of illness who were never previously exposed to antipsy chotic medications (Laruelle et aI., 1999) . Volkow et al. (1997) report a blunting of methylphenidate-induced DA release measured with C l C]raclopride in chronic cocaine abusers compared with controls, a finding replicated by Malison et al. (1999) with C 23 I]IBZM and amphetamine. These clinical results illustrate the potential of this tech nique to study alterations of DA transmission in neuro psychiatric conditions. As reviewed earlier, numerous independent laborato ries have established that e I C]raclopride and other benzamides behave as predicted by the occupancy model: higher synaptic DA levels are associated with lower ligand binding and vice versa. If the occupancy model is correct, these changes in binding retlect changes in endogenous DA. The next section reviews several arguments that either support or question the ef fectiveness of these imaging methods to measure changes in synaptic DA concentration, and the adequacy of the occupancy model on which the interpretation of these data is based.
First to be discussed are several issues and results that, in our opinion, support the use of this imaging technique to measure DA release. Appropriate model-based quan titative approaches have unequivocally documented that the decrease in benzamide-specific uptake measured fol lowing these manipulations results from a reduction in BP and not from challenge-induced changes in regional CBF (rCBF), peripheral clearance, or nonspecific bind ing. This article also reviews the experimental data con firming that these effects are mediated by DA release, and that the magnitude of these effects are correlated with the magnitude of changes in DA level as measured with microdialysis. Also reviewed is the evidence sup porting that these effects are mainly caused by synaptic changes in endogenous DA as opposed to extrasynaptic changes. Also discussed are the data supporting the use of these techniques to estimate DA levels in the "base line" or "unchallenged" state, measurements that might be important to the study of pathophysiologic conditions.
Next, this article focuses on data that raise concerns about the validity of the simple occupancy model. First, this report demonstrates that the temporal discrepancies between PET or SPECT and microdialysis measure ments significantly question this model. Next, I address the issues raised by the results obtained with spiperone and D I radiotracers. A discussion of the role of radio tracer affinity in competition studies is needed to fully appreciate the significance of the spiperone and D I ra diotracer data. This discussion leads to the proposition that the simple occupancy model might be limited in its ability to account for all of the experimental data, and that other factors might play a significant role in the alterations of BP observed following DA manipulations.
Data supporting the occupancy model
The importance of model-based methods to measure changes in binding potential. The first question is wheth er the changes in radiotracer binding measured after these challenges truly retlect changes in receptor avail ability (in this report, the term receptor availability is used to denote the BP of the receptors in the presence of a competitor such as DA). Pharmacologic interventions that induce significant changes in DA synaptic concen tration frequently affect multiple physiologic parameters such as body temperature, rCBF, peripheral rate of clear ance of the radiotracer, blood pH, and radiotracer plasma protein binding. For example, in anesthetized baboons, a single amphetamine injection (0.4 mg/kg) decreases rCBF by as much as 50% (Hartvig et aI., 1997) . These physiologic factors are known to affect radiotracer up take. Therefore. a receptor parameter quantification method resistant to variations in these physiologic pa rameters must be implemented for appropriate evaluation of the effect of these challenges on receptor availability. Several quantification methods have been developed to address these concerns, referred to here under the generic term of model-based methods. I consider here the rela tively simple case of reversible radiotracers such as e I Clraclopride or [ 123 1]lBZM.
Control for the effect of the challenge on rCBF and peripheral clearance. The effect of increased DA levels on benzamide BP has been detected using two general experimental strategies. termed "blocking" and "dis placement" experiments, as in competition experiments using exogenous competitors. In blocking experiments, changes in receptor occupancy by DA are induced before radiotracer administration, and receptor parameters are compared with those measured under control conditions. In displacement experiments, the pharmacologic chal lenge is given after administration of the radiotracer.
Regarding blocking experiments, a variety of model based methods have been used to analyze the challenge effects on BP. For [ II C]raclopride, these methods in clude kinetic three-compartment modeling using the ar terial metabolite-corrected tracer concentration as input function (Carson et aI., 1997; Price et aI., 1998; Abi Dargham et aI., 1999) , the Logan et al. (1990) graphical method for reversible tracers (Dewey et aI., 1992; Dewey et aI., 1993; Volkow et aI., 1994; Dewey et aI., 1995 ; Volkow et aI., 1997; Smith et aI., 1998; Volkow et aI., 1999) , the two-compartment model using the cerebellum as input function (Kobayashi et aI., 1995; Koepp et aI., 1998) , or the peak equilibrium method (Farde et aI., 1992; Ginovart et aI., 1997; Hartvig et aI., 1997; Ginov art et aI., 1998) . These methods generally enable mea surements of receptor parameters that are independent from rCBF or peripheral clearance. For example, deriva tion of [ II Cjraciopride k 3 /k4 ratio by the three compartment kinetic modeling and the graphical method of Logan et al. (1990) are unaffected by changes in rCBF (Logan et aI., 1994) .
However, these methods assume the rCBF to be con stant during the time frame of the scan. These methods effectively correct for changes in rCBF between a base line and a challenge scan if these changes are sustained during the scanning period, but they are vulnerable to variations in rCBF that occur during the scan. An initial decrease followed by an increase in rCBF might cause a time-activity curve kinetically indistinguishable from a curve resulting from a decrease in BP availability. The potential of these rCBF effects to induce artifactual re sults might not have received enough attention. These phenomena might contribute to some of the surprising results found in the literature, suggesting, for example, that video game playing elicit a greater DA release than intravenous cocaine.
Results from displacement experiments performed during the regional washout phase of the radiotracer are even more difficult to interpret. In several studies, the effect of the challenge was assessed by comparing the radiotracer washout rate following the challenge to this rate measured under control conditions. For example, amphetamine increased the striatal washout rate of e 2 3 I]IBZM (Innis et aI., 1992) , e S Flfallypride (Kessler et aI., 1993; Mukherjee et aI., 1997) , and [ 18 F]FCP (Mach et aI., 1997 ). Yet, increase in the peripheral clear ance of the tracer or increase in rCBF also increases the radiotracer washout rate. This issue was formally ad dressed by Dagher et al. (1998) , who showed that both an increase in k 2 (from increased rCBF) or a decrease in k 3 (from decreased BP) induced during the washout phase could result in similar curves. Thus, this design is not appropriate to establish an effect of the challenge on receptor availability. For e 23 I]IBZM and [ l s FJfallypride, the amphetamine-induced reductions in BP initially sug gested by the wash-out rate method (Innis et aI., 1992; Kessler et aI., 1993; Mukherjee et aI., 1997) were con-firmed with more robust methods (Laruelle et aI., 1997b; Price et aI., 1998) .
A better method for displacement experiments is to administer the radiotracer as a bolus followed by con stant infusion, wait for the establishment of a sustained equilibrium state, and inject the challenge drug during the equilibrium period (Fig. 2) . Under those conditions, an effect on the peripheral clearance will result in a change in the plasma steady-state level of the radiotracer, and the incorporation of this information in the outcome measure will correct for this effect. Variations in rCBF will not affect the equilibrium because, during sustained equilibrium state, there is no net radiotracer transfer across the blood-brain barrier (BBB Control for the effect of the challenge on plasma and brain nonspecific binding. Although several tech niques are available to control for the effect of the chal lenge on rCBF or peripheral clearance, the problem of challenge-induced changes in nonspecific binding in the brain or the plasma is more difficult to address. Discuss ing this problem requires the researcher to scrutinize the various acceptations of the ubiquitous term "binding po tential." This term encompasses at least three different outcome measures. A variety of nomenclature systems have been developed to clarify this situation; two of them (Laruelle et aI., I 994c; Carson et aI., 1997) are presented in Table 6 .
Ignoring the presence of the competitor DA, the ra dioligand specifically bound concentration (B) is, at
90
Time ( B ,m", density of available binding sites; Kj), affinity of the radiotracer for available binding sites; f " radiotracer plasma free fraction; V 2' distribution volume of nondisplaceable (free and nonspecifically bound) compartment; K, and k2, rate constants for transit of the radiotracer between plasma and nondisplaceable compartment; k, and k4, rate constants for transit of the radiotracer between nondisplaceable and specific binding compartment; OV, total tissue distribution volume relative to total radiotracer concentration, equilibrium, related to the radioligand free concentration (F), the maximal number of D2 receptors (Bm ax ), and the equilibrium dissociation rate constant of radio ligand for D2 receptors (KD) by the Michaelis-Menten equation
If the radioligand is administered at tracer dose, F is negligible relative to Ko and this equation simplifies to (2) Eq, 2 can be rearranged to demonstrate the equiva lence between the BP and the B/F ratio,
Eq, 3 indicates that BP is equal to the ratio of the specifically bound (B) concentration to the free ligand concentration in the vicinity of the receptors (F), when these terms are at equilibrium and when the tracer doses of the radio ligand are used,
The radiotracer usually is assumed to distribute into three compartments: the plasma compartment (C l ), the brain nondisplaceable compartment (C2, which includes both free and nonspecifically bound radiotracer), and the receptor compartment (C 3 ), Defining that Vi is the equi librium distribution volume of a brain compartment rela tive to the free radiotracer concentration in the brain, V 2 and V 3 are the distribution volumes of the nondisplace able and receptor compartments, respectively, and V T is the total distribution volume (V T = V 2 + V 3 )' Eq, 3 shows that BP is equal to V 3 , that is, the bound over free ratio (B/F) at equilibrium.
The radioligand specifically bound concentration, B, is directly measurable as the specific binding (e.g., as the difference between striatum and cerebellum activities at equilibrium), but F, the free concentration of the radio tracer in the brain, is not directly measurable. Because the radiotracer crosses the BBB by passive diffusion, it J Cereh Blood Flow Metub, Vol. 20, No. 3, 20()() can be assumed that at equilibrium (when there is no net transfer of radiotracer across the BBB), the free concen tration is equal on both sides of the BBB, and the free plasma concentration can be substituted to the free brain concentration in Eq. 3 to calculate BP. This assumption has been validated by two observations: (1) at equilib rium, the tracer concentration in the CSF is equal to the free concentration in the plasma (Kawai et a!., 1991; Laruelle et a!., 1994a) ; and (2) the Ko measured in vivo equals the in vitro Ko when the free plasma concentra tion is used as the concentration parameter (Laruelle et a!., 1994a,b) . The radiotracer free fraction in the plasma and in the nondisplaceable compartment usually are noted as f l and f 2 , respectively. At equilibrium, C l f l = Ci2' It follows that the nondisplaceable distribution vol ume, V 2' is equal to I/f2. Thus, calculation of BP as V 3 represents the "ideal" measurement of BP because the denominator F does not include any nonspecific compo nent. The use of this outcome measure requires the mea surement of the free fraction in the plasma (f l ).
The plasma free fraction (1' 1 ) is difficult to measure with accuracy, especially for radiotracer with high bind ing to plasma proteins. Therefore, BP sometimes is ex pressed relative to the total (bound or unbound) plasma concentration, and the term V 3 ' is used to designate this ratio. More often, BP is expressed relative to the total (free plus nonspecifically bound) brain concentration in a region of reference devoid of specific binding, and the term V 3 /1 is used to designate this ratio. In the terminol ogy of , V 3 , V 3 " and V 3 /1 are desig nated S', S, and R, respectively. U sing the kinetic notation of a three-compartment model (plasma, nondisplaceable and specific compart ments), V 3 is given by K,k 3 /k2k4f l ' V 3 ' is given by K,k 3 1 k2k4 ' and V 3 /1 is given by k 3 ik4' The equivalence between this terminology and the terminology derived from the graphical analysis of Logan et a!. (1990) also is given in Table 6 . Each of these outcome measures have distinct advantages and limitations (see discussion in Abi Dargham et a!., \999).
The importance of the choice of outcome measure in the estimation of changes in receptor parameters induced by a challenge can be appreciated in Table 2 of . Using graphical analysis, amphetamine (OA mg/kg) induced a 42% ± 17% reduction in V 3 (S'), a 29% ± 21 % reduction in V 3 ' (S), and a 36% ± 15% reduction in V 3 ' (R). A major advantage of V 3 " is the highest test-retest reproducibility of this outcome measure compared with V 3 ' and V 3 (Logan et aI., 1994; Abi-Dargham et aI., 1995; Carson et aI., 1997) . Because the magnitude of the challenge effect generally is small, it is reasonable to select the outcome measure attached with the lowest tes t-retest variability, and V 3 " has been the outcome mea sure of choice for clinical studies (Laruelle et aI., 1996; Breier et aI., 1997; Volkow et aI. , 1997; Abi-Dargham et aI., 1998) . This choice is based on the assumption that the challenge will not affect the nondisplaceable distri bution volume in the brain (V 2), that is, the nonspecific binding.
Yet, this assumption generally is not valid. For ex ample, changes in radiotracer cerebellum distribution volume (V 2 ' = V 2f,) often are measured during chal lenge tests (see, for example, Table I in Dewey et aI., 1993 ). If f, is not measured (a situation where V 3 is not available), it is impossible to decide if this change in cerebellum distribution volume results from a change in nonspecific binding in the plasma (l/fl) or the cerebel lum (1/f2)' Using V 3 " as outcome measure effectively controls for changes in f" since f, cancels out in the V 3 1V 2 ratio, but leads to artifactual results if the change is in f2. Using V 3 ' as outcome measure effectively con trols for changes in f2, since V 2 is not included in the outcome measure, but the result will be biased if the change in V 2 ' is caused by change in f l ' Since the am phetamine effect on [ I I Clraclopride-specific binding has been demonstrated with each of the three outcome mea sures, there is no doubt that, at least with this tracer, amphetamine induces a reduction of the Bmax/K[) ratio. However, in the absence of accurate measurement of fl ' it is not possible to control for the potential impact of the challenge on plasma and brain nonspecific binding.
DA release is required fo r the effect of amphetamine on D2 receptor binding potential. In the previous section, this article reviews the evidence supporting that changes in [ " C]raclopride-or r I 23 I]IBZM-specific uptake after DA manipulations effectively result from changes in BP, and not from artifacts caused by alterations in rCBF, peripheral metabolism, or nonspecific binding. The next question is whether these changes in BP are mediated by changes in synaptic DA concentration. Several experi ments directly confirm that changes in benzamide ' s BP fo llowing amphetamine are dependent on changes in DA release.
Amphetamine induces DA release by reverse transport of DA from the cytoplasmic pool to the synapse through the DAT (Fischer and Cho, 1979; Sulzer et aI., 1995) . Thus, blocking DAT with DA uptake inhibitors such as nomifensine results in a blunting of amphetamine induced DA release (Fischer and Cho, 1979; Raiteri et aI., 1979; Connor and Kuczenski, 1986; Parker and Cu beddu, 1986; Butcher et aI., 1988; Simon et aI., 1991) . Because amphetamine releases DA from the cytoplasmic pool, amphetamine-induced DA release is dependent on new DA synthesis and on the functional activity of ty rosine hydroxylase. Thus, the inhibitor of tyrosine hy droxylase, AMPT, significantly reduces amphetamine induced DA release (Butcher et aI., 1988; Nash and Ya mamoto, 1993; Cadoni et aI., 1995; Laruelle et aI., 1997 b) . Finally, at high doses, amphetamine redistributes DA from the vesicular to the cytoplasmic pool (Sulzer et aI., 1993; Sulzer et aI., 1995) . Thus, reserpine pretreat ment affects amphetamine-induced DA release, at least after high doses of amphetamine (Dluzen and Liu, 1994; Cadoni et aI., 1995; Florin et aI., 1995; Pift et aI., 1995) . It is therefore expected that the DA uptake blockers AMPT and reserpine should diminish the effect of am phetamine on [ ' I CJraclopride or [ 1 23 I]IBZM BP.
The first demonstration that this was the case was provided by Innis et al. (1992) in baboons. Reserpine pretreatment resulted in significant blunting of the am phetamine-induced increase in [ 1 23 IjIBZM washout rate. Next, it was established that AMPT pretreatment blocked the effect of amphetamine on [ 1 23 I]IBZM BP, as mea sured during radiotracer constant infusion paradigm (La ruelle et aI., 1997b). Recently, Villemagne et al. (1988) showed that pretreatment with the DAT blocker GBR 12909 blocked the effect of amphetamine on [ I I C Jraclo pride BP, as measured during radiotracer constant infu sion paradigm. Together, these data provide firm evi dence that the effect of amphetamine on benzamides BP requires enhanced DA release.
Quantitative relationship between DA release and change in D2 receptor binding potential. Because this imaging technique was proposed as a measure of DA transmission, it was important to characterize experimen tally the relationship between extracellular DA and ra dioligand displacement.
The first step was to demonstrate the existence of a dose-effect relationship between challenge drug and ra diotracer displacement. Laruelle et al. (1997 b) showed a dose-dependent effect of three doses of amphetamine on [ 1 23 I]IBZM BP in baboons: [ 1 23 IJIBZM BP was reduced by 20% ± 5%, 28% ± 7%, and 38% ± 10% after 0.3-, 0.5-, and I.O-mg/kg amphetamine doses (n = 3), respec tively. Breier et al. (1997) report the effect of two doses of amphetamine on [ II CJraclopride BP in rhesus mon keys: [ I I Clraclopride BP was reduced by 10% ± 5% and 21 % ± 5% after 0.2-and OA-mg/kg amphetamine doses, respectively (n = 4). Hartvig et al. (1997) administered amphetamine using constant infusion to achieve steady-state plasma amphetamine ranging from 0.2 to 25 ng/mL in rhesus monkeys and showed an increased reduction in [ " C]raclopride BP following an increasing amphetamine plasma level.
The next step was to characterize the magnitude of DA release elicited by these various doses of amphetamine in anesthetized primates. Laruelle et al. (l997b) report mi crodialysis measurements of DA release in one vervet monkey after five doses of amphetamine, ranging from 0.03 to 1.5 mg/kg. Breier et al. (1997) performed simul taneous microdialysis and PET experiments (four rhesus monkeys and two amphetamine doses). In both studies, the relationship between combined microdialysis mea surements and combined radiotracer displacements at each amphetamine dose was characterized. These analy ses yielded consistent results. Linear correlation between microdialysis and SPECT measurements revealed that each percent decrement in [ ' 2 3 T]IBZM BP corresponded to a 44% increase of peak DA concentration following DA (Fig. 3) . Likewise, each percent decrement in [ " CJraclopride BP corresponded to a 44% DA increase for the 0.2-mg/kg dose, and 64% DA increase for the OA-mg/kg dose. Both studies indicate that a large in crease in extracellular DA release (range, 400% to 1500%) is associated with a relatively small effect on radiotracer BP (decrease range, 10% to 38%), but that these effects were correlated, supporting the usefulness of the imaging paradigm in providing noninvasive mea surement of DA release.
However, closer examination of the data reveals some limitations to these conclusions. In the study by , the microdialysis and PET measurements were obtained simultaneously. Therefore, these data pro vided the opportunity to examine the relationship be tween microdialysis and PET measurements within each experiment. Examination of the data from Tables 1 and 2 of the report by Breier et al. (1997) reveals a lack of relationship between microdialysis and PET measure ments collected within the same experiment. For ex ample, rhesus 2 showed the larger increase in extra cellular DA after the 0.2-mg dose (+ 1000%), but [ " C] raclopride BP was not affected. Rhesus 3 showed the larger effect of the 0.2-mg/kg amphetamine dose on [ " C]raclopride BP (decrease by 19.2%) but showed only a modest 116% increase in extracellular DA. These discrepancies suggest that a large noise is associated with both measurements and that the data at each dose must be averaged yield a meaningful relationship. Alternatively, these results might indicate that the extracellular DA level is not the only factor playing a role in determining the magnitude of the change in [ " C]raclopride BP. Discussion of the ceiling effect. Decreases in [ ' ' C]ra clopride and [ 1 2 3 I]IBZM BP have been measured after several challenges, and the literature is consistent in the range of radiotracer displacement (less than 50%). Table  7 lists the mean ± SD and the range of [ " C]raclopride and [ ' 2 3 IJIBZM BP reduction after a single administra tion of psycho stimulants measured with PET or SPECT in nonhuman primates and humans. The sorting order in the Table 7 is species, radiotracer, challenge drug, and dose. Inspection of Table 7 clearly indicates that only about half of the radiotracer-specific binding is affected by psychostimulant challenges.
This ceiling effect is not inconsistent with the occu pancy model. The D2 receptors are configured in states of high or low affinity for agonists, with approximately 50% of the receptors contributing to each state in vitro (Zahniser and Molinoff, 1978; Sibley et aI., 1982; George et al., 1985a; Seeman and Grigoriadis, 1987; Richfield et aI., 1989) . The antagonists [ ' 2 3 I]IBZM and [ " C]raclopride bind with equal affinity to both states. The agonist DA is not expected to compete efficiently with [ ' 2 3 I]IBZM or e ' C]raclopride binding to D2 recep tors in the agonist low-affinity configuration. This factor alone would leave only about 50% of the antagonist binding susceptible to endogenous competition. In addi tion, not all receptors configured in the high-affinity state are available to the binding of the radiotracer at baseline, since a proportion of these high-affinity state receptors is expected to be occupied by baseline levels of endog enous DA. Assuming that 50% of the sites are configured in the agonist high-affinity state and that 20% are already occupied by DA at baseline (i.e., before the challenge), only about 30% of the total receptor population (i.e., 37.5% of receptors contributing to baseline [ " C]raclo- pride or [ 1 23 1]IBZM BP) will be susceptible to an addi tional occupancy by DA following the challenge (Fig. 4) .
Displacement studies with agonists in mice confirm that only 10% to 30% of the D2 sites satisfy both con ditions of being in the high agonist affinity states and not being occupied by DA under resting conditions (Ross and Jackson. 1989b ). Moreover. many D2 receptors are not located in the synaptic cleft, and extrasynaptic recep- (Table 7) . It is assumed that (1) 50% of receptors are in high and low affinity states for DA, respectively; (2) 20% of re ceptors are already occupied by DA at baseline, that is, before the challenge, and are not available for [1 1 C]raclopride binding; and (3) DA does not bind effectively to D 2 receptors that are in the low-affinity configuration. It follows that only 30% of total D2 re ceptors (i .e., 37.5% of receptors available to [ l lC]raclopride) will be vulnerable to an increase above baseline of DA concentration.
tors might be less exposed to changes in DA release compared with receptors located at the synaptic level (Levey et a!., 1993; Smiley et aI., 1994; Caille et aI., 1996) . Given these factors, it is not surprising that DA would displace only up to 50% of the in vivo binding of [ I I Clraclopride and C 23 IjIBZM, and the existence of this plateau effect is not inconsistent with the occupancy model. Synaptic versus extrasynaptic location of the effect. As eluded to in the previous section. not all D2 receptors are located within the synaptic clef. In striatal dendritic spines. as much as 50% of D 1 and D 2 receptors might not be associated with synapses . In ad dition. receptors associated with synapses were more of ten associated with asymmetrical synapses that usually receive input from glutamateric corticostriatal afferents than with symmetrical synapses. usually associated with terminals of nigrostriatal projections (Levey et aI., 1993; . Thus, whereas the proportion of synaptic versus nonsynaptic D I and D2 receptors is not precisely known, it is clear that a non negligible number of these receptors are located at sites distant from dopaminergic synapses.
Microdialysis measurements are performed in the ex trasynaptic extracellular compartment, where the base line concentration of DA is estimated to be in the 20-to 40-nmollL range (Church et aI., 1987) . The DA concen tration probably is higher within the synapse. Using fast scan voltametry measurement of DA release at the syn aptic interface, Kawagoe et ai. (1992) estimated that the synaptic concentration of DA rapidly varies from as high as 200 nmollL to as low as 6 nmol/L, with a temporal average of about 100 nmollL (May 1988) . In normal conditions, rapid uptake of synaptic OA by OAT is thought to prevent OA released in the synapse from dif fusing to the extrasynaptic space (Grace, 1993) . Support ing this view is the absence of changes in extracellular OA elicited by electrical stimulation of OA neurons at frequencies lower than 10 Hz (Kuhr et a!., 1984; Kuhr and Wightman, 1986; May, 1988) . Intrasynaptic OA is increased at these frequencies, since OA-mediated be havioral effects are induced. The role of OAT in pre venting intrasynaptic OA to diffuse to extrasynaptic space is confirmed by the increase in extrasynaptic OA elicited at these low frequencies when a OAT blocker is coadministered (see discussion in Grace, 1993) . Grace (1991 Grace ( , 1993 proposed the terms phasic release to char acterize the intrasynaptic release elicited by cell firing and tonic release to characterize the low level of extra synaptic release that is independent of cell firing.
If the effects of endogenous OA competing with ra dioligand were located mostly at the nonsynaptic O2 re ceptors, it would be expected that microdialysis measure ments and decrease in [ I I C]raclopride BP would be re lated across several pharmacologic challenges. Evidence suggests that this is not the case. Nicotine, a drug that stimulates OA cell firing without blocking OAT, induces only a modest increase in extrasynaptic OA concentra tion. In rodent, a high dose of nicotine (5 mg/kg) elicits only a 29% increase in extrasynaptic OA measured with microdialysis (Kim et a!., 1998 ). Yet, this dose of nico tine was associated with a 21 % decrease in [ 3 Hlraclo pride in vivo binding (Kim et a!., 1998) . In contrast, the dose of amphetamine (0.4 mg/kg) associated with the same 21 % decrease in [ II C Jraclopride in rhesus monkeys elicits a 1365% increase over baseline in extrasynaptic OA (Breier et aI., 1997) .
This apparent discrepancy is explainable by the dif ferences in the OAT blocking properties of these drugs. Extrasynaptic OA reflects intrasynaptic OA following OAT blockers such as amphetamine, but not fo llowing drugs like nicotine, which stimulate OA release without blocking OAT. Because a similar reduction in raclopride BP (2 1%) is observed following nicotine (5 mg/kg) and amphetamine (0.4 mg/kg) challenges associated with 29% and 1365% increase in extracellular OA, respec tively, the challenge must affect mainly the BP of O2 receptors located within the synaptic cleft.
Similar results have been reported (Tsukada et aI., 1999) . The OA extracellular concentrations and [ II CJra c\opride displacements were measured in unanesthetized monkeys after the administration of "direct" OA enhanc ers (OAT blockers GBR 12909 and methamphetamine), and "indirect" enhancers, that is, the muscarinic antago nist benztropine (at a dose not expected to block OAT) and the 5HT 2A antagonist ketanserin. Again, at similar level of [ 11 C]rac\opride BP decrease, the magnitude of J Cereh Blood Flow Metab, Vol. 20, No. 3, 20()0 OA extracellular increase following direct enhancers was much larger than following indirect enhancers, which is expected because only direct enhancers blocked OAT. These results also are consistent with a predominant in trasynaptic location of the effect measured with PET.
Thus, the discrepancies across pharmacologic agents in their ability to affect OA microdialysis and benzamide BP measurements is not inconsistent with the occupancy model, if it is accepted that the effect on benzamide BP primarily occurs within the synaptic space.
Occupancy of D2 receptors by baseline levels of do pamine. Endogenous competition studies thus might be the only tool available to estimate intrasynaptic O2 re ceptor occupancy by OA and intrasynaptic OA levels. Across studies, results are consistent in indicating that a substantial proportion of O2 receptors are occupied by OA under physiologic conditions. Inhibition and deple tion studies presented in Tables 2 to 4 indicate that 20% to 30% of O2 receptors are "unmasked" by removal of endogenous OA. These estimates are valid to the extent that the OA depletion is sufficiently acute to allow un masked O2 receptors to be measured before significant receptor upregulation occurs (Larue lie et a!., 1997a).
Knowledge of the baseline occupancy permits an es timation of baseline OA concentration in the vicinity of O2 receptors (Ross and Jackson, 1989b; Laruelle et a!., 1997a) . These estimates are based on Eq. 4 describing the equilibrium binding of a radioligand in the presence of a competitor, in this case, OA (Bylund and Yama mura, 1990) 
where FDA is the temporal average concentration of free OA in the vicinity of receptors, and K J is the inhibition constant of DA for radioligand binding to O 2 receptors. Assuming that the KI of DA to inhibit CH]NP A binding in vivo was similar to the value measured in vitro at 37°C (101 nmollL), and assuming that reserpine (5 mg/kg sub cutaneously 3 days before experiment) pretreatment re sulted in complete OA depletion, Ross and Jackson (I 989b ) estimated the OA synaptic concentration at 36 nmol/L. Using a similar approach, a K J value of OA to inhibit [ 1 23 1]JBZM binding of 160 nmollL (BrUcke et a! ., 1988), and data from AMPT depletion challenge in hu mans, Laruelle et a!. (1997 a) estimated the average syn aptic OA concentration in humans within the 45 to 72 nmol/L range. These estimates are not too far from the temporal average synaptic OA concentration of 100 nmol/L derived from voltametry studies (Kawagoe et aI., 1992) . Nonetheless, given the number of unknowns such as the exact K J of OA for O2 receptors in vivo, the pro portion of high and low affinity state and their respective Khi g h and Klow, the proportion of synaptic versus extra-synaptic and internalized versus noninternalized recep tors, these quantitative estimates should be viewed with caution. The important point is that the increase in benz a mide BP induced by acute DA depletion might be used to quantify the proportion of D 2 receptors unmasked by the removal of endogenous DA (Laruelle et aI., 1997a) . This method might provide an indirect measure of synaptic DA concentration under baseline conditions, which is driven by the phasic activity of DA neurons.
Equation 4 assumes that the interaction between DA and D2 receptor antagonists is purely competitive, that is, that the presence of the competitor DA affects the ap parent Ko of the radiotracer but not the Bmax. The ques tion of the competitive or noncompetitive nature of the interaction between DA and D2 receptor antagonists is important. If the interaction was purely competitive, DA levels would affect Ko and not Bmax, and the Ko of the radiotracer measured in vivo might provide an indirect information about levels of endogenous DA. If the inter action was purely noncompetitive, DA levels would af fect Bmax but not Ko. If the interaction was mixed, DA levels would affect both Ko and Bmax.
Th e nature of the interaction between dopamine and antagonist at D2 receptors. In vitro data are consistent in showing that interactions between DA and D2 receptor antagonist follow a mixed model: this interaction appears to be competitive at the receptors configured in low ago nist affinity state, and noncompetitive at the receptors configured in high agonist affinity state. Saturation ex periments performed with eH]spiperone in the absence and presence of the agonist NPA (50 nmol/L) reveal that NPA reduced the Bm,lX of [ 3 H]spiperone, with no appar ent change in the Ko (Sibley and Creese, 1980) . How ever, when the experiment was performed in the pres ence of nonhydrolyzable G-protein analogs to convert the high agonist affinity sites into low agonist affinity sites, the interaction was strictly competitive, that is, NPA affected the Ko but not the Bmax of [ 3 H]spiperone (Sibley et aI., 1982) . Interactions between eH]spiperone and DA and other agonists also was shown to be mixed, with both competitive and noncompetitive components (Leysen and Gommeren, 1981; Chatterjee et aI., 1988) . Guanine nucleotides increase the Bmax of spiperone with no effect on the Ko' whereas this effect is abolished by extensive washing of the membranes (which removes endogenous DA) and is restored by adding DA to the incubation medium (George et aI., 1985b) . This mixed interaction, originally described for eHJspiperone, also was noted with eHJraclopride (Seeman et aI., 1989; Hall et aI., 1990; Seeman et aI., 1990) .
In vivo, the situation is less clear. Although the inter action between eHJraclopride appears to be mixed in mice (acute DA depletion reduces Ko and increases Bmax) (Ross and Jackson, 1989a) , recent data in anesthe tized primates obtained with [ I I C]raclopride are consis-tent with a pure competitive interaction (Ginovart et aI., 1997) . Thus, whereas in vitro studies are consistent in detecting both competitive and noncompetitive interac tions between DA and r " ClNMSP or [ ' I C]raclopride, the existence of both components has not been consis tently documented in vivo, and more data are needed to resolve this issue.
Whether the presence of endogenous DA affects the antagonist Bmax, Ko, or both is an important question, but this issue is not crucial to the interpretation of changes in radioligand BP following DA manipulations when measured at tracer doses of the radioligand. In creased DA level might reduce the number of sites avail able to the radiotracer or might reduce the affinity of these sites for the radiotracer. Both of these effects will translate in a reduction of BP (Bma)KO)' Thus, the ex istence of these complex interactions does not invalidate per se the occupancy model
Data questioning the occupancy model
After examining the results that support or are consis tent with the general occupancy model as a theoretical construct for the interpretation of these experiments, this report focuses on results that are not easily accounted for by this model.
Long-lasting effect of amphetamine on binding poten tial. A first observation difficult to reconcile with the occupancy model is the long-lasting effect of the short lived amphetamine-induced DA surge on D2 receptor availability. Studies performed with amphetamine and r 1 23 I1IBZM reveal a significant temporal discrepancy be tween microdialysis and SPECT measurements. Follow ing amphetamine, the rapid increase and decrease of ex tracellular DA in the extracellular space did not match the slow and prolonged decrease in [ 1 23 I]IBZM BP in duced by amphetamine (Laruelle et aI., 1997b) . Micro dialysis data show that extracellular DA peaked within 10 to 20 minutes after amphetamine and that this peak was followed by a rapid decrease in extracellular DA. Microdialysis measurements were obtained up to 120 minutes following amphetamine. In the 100-to 120minute postamphetamine collection (endpoint of data collection), extracellular DA concentration was still el evated compared with baseline but at levels much lower than peak levels (34% ± 5.3% of peak value). Thus, the DA surge in extracellular milieu is relatively short-lived.
In contrast, the specific binding of [ 1 23 I]IBZM de creased for 60 to 90 minutes following amphetamine and stabilized thereafter at levels lower than baseline.
[ 1 23 I]IBZM-specific binding was measured for up to 240 to 300 minutes after amphetamine challenge in numerous experiments (Laruelle et aI., 1997b) . Without exception, the [ 1 23 1]IBZM BP still was decreased at its nadir level at these later time points. Such information was not avail able until recently for [ " Clraclopride. Experiments per-formed with multiple injections of [ 11 C]raclopride con firm the original observation made with C 23 I]lBZM (R. Carson, personal communication, 1999) . Up to 5 hours following amphetamine, [ II C]raclopride BP still is de creased at its lower level. The delay between the peak of DA release and the time to reach a new and lower "equilibrium" level (40 to 60 minutes with [ 11 C]raclopride, 60 to 120 minutes for [ 1 23 I] lBZM) is easily explainable by the relatively slow dissociation of the radiotracers from the receptors in vivo (Perry et aI., 1980; Frost and Wagner, 1984; Frey et aI., 1985; Laruelle et aI., 1994a; Endres and Carson, 1998; Gifford et aI., 1998) . In contrast, the sustained and stable nature of the decreased BP is more difficult to explain. At the end of the displacement phase, BP appeared to stabilize at a level lower than baseline, as if a new sus tained equilibrium state had been established. Yet, the microdialysis data showed a constant decrease in DA concentration during this period of stable reduced BP.
Consider the case of a radiotracer constant infusion (constant level of free radiotracer in the brain). After the challenge, the radio ligand should first predominantly dis sociate for as long as the actual bound is higher than the bound predicted by the receptor availability and the Mi chaelis-Menten equilibrium equation. However, once equilibrium is achieved, this equilibrium should be short lived. After this nadir, the radiotracer should predomi nantly associate, since the actual bound would be lower than the bound predicted by the receptor availability and the Michaelis-Menten equilibrium equation. Thus, the lack of reassociation of the radiotracer during that period is not consistent with the hypothesis that changes in ra diotracer BP are primarily driven by changes in DA oc cupancy of the D2 receptor. Endres et al. (1997) developed a mathematical model to assess the effect of a DA pulse on [ II CJraclopride specific binding achieved during radiotracer constant in fusion. Using simulations, these authors demonstrated that, for an average DA pulse, [ II C]raclopride-specific binding should return to half of its baseline value by the 1 10-to 120-minute postamphetamine injection. Since this is not the case, these simulations establish more for mally that the simple occupancy model based on micro dialysis data fails to account for the prolonged decrease in [ II C]raclopride BP observed following amphetamine. Thus, these kinetic analyses are important to clarify the lack of agreement between the simple occupancy model and the experimental data.
The only way to reconcile this observation with the occupancy theory is to postulate that, within the synapse, elevated and stable levels of DA are maintained during this long period. Microdialysis measurements do not rule out such a phenomenon, since extrasynaptic DA concen trations are not necessarily a good measure of intrasyn aptic DA concentration (see earlier). In addition to its J Cereb Blood Flow Metab. Vol. 20, No. 3, 20()0 DAT blocking effect, amphetamine inhibits monoamine oxidase activity (Green and El Haut, 1978) and stimu lates DA synthesis (Uretsky and Snodgrass, 1977) . It is plausible that these DA-enhancing properties are more important at this later phase than the DAT blocking reverse transport mechanism, which could explain a time-dependent dissociation between extrasynaptic and intrasynaptic DA concentration.
Also, in a recent report, Volkow et al. (1999) showed a smaller decline in [ 11 C]raclopride following cocaine (l mg/kg) when cocaine was administered 30 minutes be fore [ 11 C]raclopride (-13% decrease, n = 1) and 5 min utes before [ II C]raclopride (-29 + 3%, n = 3). These data suggest that, at least after cocaine, the decrease in [ II C]raclopride BP is transient, which is consistent with the short duration of the effect of cocaine on DA trans mission. However, additional experiments are warranted to further document this important question.
Another explanation for the long duration of decreased BP following amphetamine is that the DA surge would induce a long-lasting change in D2 receptor that would not be dependent on sustained increased occupancy of these receptors by DA. Rapid agonist-mediated receptor downregulation, internalization, or phosphorylation might account for this long-lasting decrease in BP. This point is revisited later, after discussion of the spiperone and D 1 receptor data. For now, it is proposed that the long-lasting reduction in [ 11 C]raclopride and [ 1 23 I]lBZM BP following amphetamine challenge raises doubt about the validity of the simple occupancy model, without re futing it definitively.
Radiotracer characteristics and vulnerability of en dogenous DA competition. The discrepancies between the occupancy model predictions and the data collected with spiperone and D l radiotracers constitute a second line of evidence against this model. However, the rel evance of the spiperone and D] radiotracers data can be appreciated only after clarification of the role of radio tracer affinity in vulnerability to endogenous DA com petition within the framework of the occupancy model. The role of radio ligand affinity in vulnerability to en dogenous DA is a complex topic. The initial proposition of Seeman (1989) that low-affinity radiotracers such as raclopride bind more "loosely" to D 2 receptors, and, therefore, are more vulnerable to DA competition has gained wide acceptance, possibly because of the intuitive nature of this proposition. However, this proposition vio lates well established rules of receptor-ligand competi tion. To fully appreciate this violation, two situations must be considered, that is, when levels of DA are con stant, and when they are rapidly changing.
First examine the case when both the ligand and the competitor (DA) are at equilibrium. Thus, the first ques tion is whether the KD of a radiotracer influences the ability of a competitor to affect its binding at equilib rium. The answer is negative if the radiotracer is present at tracer doses, or positive if the radiotracer is present at significant concentration. This answer is derived from the Cheng and Prusoff equation (Cheng and Prusoff, 1973) , which relates the intrinsic affinity of a competitor (K1) to its observed potency (ICso) to displace a radioli gand with an affinity of Ko, when the radioligand is present at concentration L:
When L is close to 0 (tracer dose), the denominator tends to I, and the ICso tends to KI and becomes inde pendent from Ko. The same conclusion can be drawn from Eq. 4. Table 8 shows results derived with Eq. 4 for two radioligands, [ 3 H]spiperone (Ko = 0. 1 nmol/L) and eH]raclopride (Ko = I nmoIlL), assuming DA affinity for D2 receptors of 50 nmollL and a DA concentration of 25 nmol/L. At tracer dose (L = 0.01 nmoI/L), both trac ers are similarly affected by DA (the presence of DA reduces the radioligand-specific binding by 33% in both cases). As L increases, the effect of DA is reduced for both radioligands. For example, when L is equal to K() (i.e., 50% occupancy of D2 receptors by the radioligand), DA will reduce the specific binding by only 20%. Since the Ko of l 3 H Jspiperone is smaller than the Kl) of l 3 H Jra clopride, the reduction of the DA effect resulting from nontracer doses of the radioligand will be noted at lower concentration of eH]spiperone than of eHlraclopride.
Results from Table 8 are consistent with the results de rived for [ II ClNMSP by Logan et a1. (1991) , who evalu ated with another equation the impact of DA on [ I I C]NMSP binding under equilibrium conditions, using a [ II CjNMSP concentration of l.9 pmol/mL (Logan et aI., 1991, Table VIE) . At this radioligand concentration, DA has a lower impact on C l C]NMSP than on [ II C]ra_ clopride. The authors state that their finding is in con tradiction with an earlier statement by Farde et a1. (1989) . This apparent discrepancy results from the fact that Logan et al. (1991) performed their analysis at non-negligible radioligand concentration, whereas Farde et al. (1989) considered the case of a tracer dose.
Once it has been established that, under equilibrium conditions and tracer doses, the affinity of the radioli gand does not affect its vulnerability to endogenous DA competition, the case of a pulse of DA must be consid ered, that is, the effect of a rapidly changing DA con centration. Here, the system is not at equilibrium, and the occupancy model predicts that the affinity of the radio ligand (or more exactly, its dissociation rate, ko ff ) will be an important factor. Endres and Carson (1998) provide a comprehensive analysis of the impact of radiotracer af finity to vulnerability of the binding to a DA pulse. They examine these interactions for both single-bolus and con stant-infusion administration of radiotracer. In both situ ations, the decrease in BP measured following a DA pulse will be larger when the rate of dissociation from the receptors (ko ff ) is faster (i.e., lower radio ligand affinity since Ko = koft lkon), and when the rate of clearance from the brain (k2) is faster (a result previously derived by Logan et aI., 1991) . According to these analyses, trac ers with low affinities are more suitable to endogenous competition studies involving transient changes in DA. As noted by Endres and Carson (1998) , there is a limit to this logic, since tracers with low affinity provide such a low signal-to-noise ratio that the effect of the endog enous DA pulse might not be accurately measurable.
In conclusion, within the limits of the simple occu pancy model, the affinity of the radiotracer does not im pact on its vulnerability to endogenous competition by DA if DA levels are constant during the time frame of the experiment and if the radioligand is given at tracer dose. In contrast, the affinity of a radiotracer will affect its vulnerability to a DA pulse. These conclusions are sup ported by studies performed with the high-affinity radio tracer [ 1 2 3 I]epidipride (Ko = 0.024 nmol/L) (Kessler et aI., 1991 a ,b) . Whereas amphetamine-induced D A surge did not affect the washout rate of this radiotracer (AI Tikriti et ai., 1994) , sustained decrease in endogenous DA achieved by AMPT administration resulted in in creased C 2 3 I]epidepride BP in humans (M. Fujita and R. Innis, personal communication, 1999) . The important conclusion is that the resistance of eH]spiperone to competition by endogenous DA should not be attributed to its higher affinity for D2 receptors.
Whereas this factor could explain resistance of eH]spi perone binding to a DA pulse, the lack of effect of DA depletion is not explainable by the affinity factor (Table   2) . Thus, other factors must be involved in the different sensitivity of raclopride and spiperone binding to DA depletion. These other factors are discussed in the next section.
The spiperone question. As reviewed earlier, results obtained with spiperone and analogs are inconsistent with the occupancy model. The first question is whether these paradoxical effects on spiperone BP are real or are artifacts of the difficulties to model appropriately spiper one uptake in the living brain.
First Wong et aI., 1986a) . Linear regression provides the constant Kin as the slope of the regression line, Kin, which is related to k 3 by Kin = K l k 3 /(k2+k 3 )' K l and k2 can be derived from the initial portion of the curve and the cerebellum distribution volume, respectively, making it possible to solve for k 3 . The use of the parameter Kin as an outcome measure has serious limitations: for e l C]NMSP, the normalized derivatives of Kin relative to k 3 and K I were reported as 0.51 and 0.45, respectively (Logan et aI., 1991) . Thus, a change of 10% in k 3 will result in a change of only 5% in Kin, and Kin is similarly affected by rCBF and k 3 . By extension, the use of stria tum to cerebellum ratios at a single time point or other measures based directly on Kin, such as the incorporation quotient (Dewey et aI., 1990) , will be vulnerable to flow effects. of -13%, -29%, and -94%, corresponding to an average of -45% ± 43%. The SD of the effect is much larger than the already large SD of the effect of 1 mg/kg amphet amine on [ 11 C]raclopride BP in baboons (e.g., 15% ± 9% in Dewey et aI., 1993) . In addition, the experiment re sulting in a 94% decrease in k 3 appears as a clear outlier on D 2 receptor BP has not been reported elsewhere. Us ing a larger range of amphetamine injections and a larger number of experiments (n = 8), Hartvig et al. (1997) failed to detect a significant effect of amphetamine on [l lC]NMSP k 3 . If anything, these authors detected a trend toward an increase in [ 11 C]NMSP k 3 with larger doses of amphetamine. Thus, a fair conclusion would be that no convincing effect of amphetamine on e l C]NMSP-specific binding has been demonstrated with PET, and that more experiments are warranted to eluci date this issue. This lack of effect is generally consistent with the rodent literature.
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Since early eH]spiperone studies in rodents typically used striatal-to-cerebellar ratios at one time point as out come measures, results of these studies also are poten tially affected by rCBF effects, although the kinetics of spiperone uptake is faster in rodents than in primates (Friedman et aI., 1984) . In conclusion, it seems unjustified to disregard the results of these studies as mere experimental artifacts, and it must be concluded that most of the data indicate that manipulation of DA system does not impact on spi perone-specific binding in a manner consistent with the occupancy model. It has already been established that the relatively higher affinity of [ lI C]spiperone for D2 recep tors is not an adequate explanation for the behavior of this radioligand vis-a-vis DA, despite being frequently quoted. Although koff and k2 might play a role in the vulnerability to a DA surge, as discussed earlier, these factors are not expected to play a role in depletion stud Ies.
If spiperone, at tracer dose, is not affected by sustained change in endogenous concentration, it is important to consider the hypothesis that the binding sites of spiper one and benzamides to D2 receptors might be different, and that DA would display higher affinity for benza mides than spiperone. This hypothesis is well supported by in vitro data from laboratories that measured DA in hibition of eH]raclopride and eH]NMSP binding in the same conditions. In vitro, 100 nmollL DA displaced 19% of eH]NMSP but 50% of l 3 H]raciopride binding (See man et aI., 1989) . Hall et al. (1990) report DA Khigh and K 1 0w values of 17.8 and 1100 nmollL for l 3 H]raciopride, and 714 and 65,500 for eH]NMSP, respectively. The best explanation for this difference is that the raclopride binding site on D2 receptor is more closely related to the DA binding site than the spiperone binding site.
Other interesting differences between spiperone and raclopride binding to D2 receptors have been reported. In vitro, the Kr of most D2 antagonists measured against [ 3 H]raclopride is lower than measured against eH]spi perone binding (Seeman et aI., 1997; Seeman and Tall erico, 1998) . The same phenomenon is observed in vivo:
the plasma haloperidol concentration corresponding to 50% occupancy of [ II C]NMSP and [ II C]raciopride bind ing sites to D2 receptor are 3 to 5 ng/mL and 0.4 to 0.6 ng/mL, respectively (Wolkin et aI., 1989; Nyberg et aI., 1995; Kapur et aI., 1997) . (Ng et aI., 1994) , and from the direct observation that benzamides label both dimers and monomers, whereas butyrophenones label only mono mers (Ng et aI., 1996a,b) . This preferential binding of spiperone-Iike compounds to the monomer configuration also was confirmed with photolabeling experiments (Zawarynski et a!., 1998) . However, the potential rela tionship between D2 receptor oligomeric states and vul nerability to endogenous DA competition has not been documented.
The documentation of a lower affinity of DA for spi-perone-butyrophenone binding sites than for raclopride benzamides binding sites would be consistent with little or no effect of DA manipulation on eH]spiperone or [ II C]NMSP. But this factor alone does not explain the paradoxical effects observed in many studies (Saelens et aI., 1980; Chugani et aI., 1988; Bischoff et a!., 1991; Inoue et a!., 1991; Pellevoisin et aI., 1993; Hartvig et a!., 1997) . A hypothesis to explain this effect has been ad vanced by Chugani et al. (1988) . These authors propose that agonist-mediated internalization of D2 receptors re sult in a trapping of l 3 Hjspiperone inside the cells, a mechanism that would be responsible for an apparent increased affinity (i.e., slower koff) and increased BP. Before discussing this view in greater detail, this article examines results from endogenous competition studies performed with D I receptor radioligands.
The D I receptor question. In vivo, the DA pulse in duced by amphetamine failed to affect several D I radio tracers, including e I C]NNC 756 (Abi-Dargham et a!., 1999), e I C]SCH 23390 (Abi-Dargham et aI., 1999; Chou et aI., 1999) , and [ II C] NNC 112 (Chou et aI., 1999) , as well as the binding of the D I agonist [ II C]SKF 82957 (Greenwald et a!., 1998; Laruelle et aI., 1998) .
The DA depletion by reserpine decreased the binding of eH]SCH 23390 in rodents (Inoue et a!., 1991) and did not affect the binding of [ ll C]NNC 112 in primates. Again, the "affinity" factor is unlikely to explain these fi ndings, since the affinities of these radiotracers are in the same range as the affinities of several D2 receptors ligands that are vulnerable to endogenous DA (Table I) .
The lack of in vivo effect of amphetamine on e I C]SCH 23390 was not expected, since Gifford et a!. (1996) , us ing a superfused brain slice preparation, detected a sig nificant displacement of eH]SCH 23390 binding fo llow ing electrically stimulated DA release. This discrepancy shows the limits of in vitro preparations to mimic the in vivo situation.
The lack of effect of amphetamine on D I radioligand binding might be explainable by factors specifically re lated to D I receptors. Yet, factors potentially accounting for differences in vulnerability to endogenous competi tion between D I and D2 antagonists binding are uncer tain. Affinity of DA for D I receptors measured in vitro appears to be in the same range as its affinity for D2 receptors (see affinity tables in Seeman, 1993) . For ex ample, in primate striatum, Madras et al . (1988) , as reported by both laboratories, illustrates how sen sitive is the determination of these values to assay conditions and analysis methods. Another unknown is the proportion of Dj receptors in high-versus low affinity states for DA in vivo. Again, in vitro studies do not document a systematic difference between Dj and D2 receptors in terms of their respective proportion of re ceptors in the high-versus low-affinity state (Hall et aI., 1988; Madras et aI ., 1988) . Moreover, Dj receptors that are in high-affinity state for agonists are expected to be preferentially labeled with the agonist [ jj C]SKF 82957.
Preliminary results indicate that e j C]SKF 82957 BP is not affected either by reserpine or amphetamine (Green wald et aI., 1998; Laruelle et aI., 1998) . The location of receptors relative to the DA release site is another factor that must be taken into consider ation. A study from Ann et al. (1998) documents that a lower proportion of Dj receptors are located in the syn aptic cleft compared with D2 receptors. This factor might explain why D j radiotracer binding is less affected by changes in endogenous DA compared with D2 radiotrac ers. However, Dj receptors are rapidly internalized in vivo following amphetamine (Dumartin et aI ., 1998) , suggesting that, despite their predominant extrasynaptic location, Dj receptors are significantly affected by am phetamine-induced DA release.
In addition, the paradoxical increase in [ 3 H]SCH 23390 reported in one study following MK-801 is in triguing (Kobayashi and Inoue, 1993) . The increased DA release elicited by NMDA blockade has been consis tently shown to decrease raclopride binding (Kobayashi et aI., 1995; Ginovart et aI., 1998; Breier et aI., 1998; Smith et aI., 1998) and to increase spiperone binding (Onoe et aI., 1994; Kobayashi et aI., 1995) . Thus, after NMDA blockade, [ 3 H]SCH 23390 behaves more in a spiperone-Iike manner than in a raclopride-Iike manner. Further exploration of this interesting response is war ranted.
In conclusion, the lack of effect or the paradoxical effect of DA manipulations on D j radiotracer binding are not easily accounted for within the framework of the occupancy theory. The paradoxical response detected in several experimental conditions forces the potential im portance of other mechanisms, such as agonist-mediated endocytosis, to be considered.
Agonist-mediated receptor internalization. Endocyto sis-mediated internalization of G-protein-coupled recep tors in response to agonist stimulation is one of the nu merous mechanisms by which cellular responses to ago nists are rapidly attenuated (Feger et aI ., 1994; Grady et aI., 1997; Koenig and Edwardson, 1997) . Rapid agonist mediated internalization to endosomal compartment has been documented for numerous G-protein-coupled re ceptors (Maloteaux and Hermans, 1994 ; Faure et aI., 1995; Fonseca et aI., 1995; Mantyh et aI., 1995 Sternini et aI., 1996; Barak et aI., 1997; Roth et aI., 1998) . Following endosome formation, acidifica tion of the endosomes permits dissociation of the ago nist-receptor complex. The receptor can be recycled to the membrane, whereas the agonist is degraded (see ref erences in Grady et aI., 1993) . Rapid internalization of D2 receptors in face of an agonist challenge has been demonstrated in several transfected cells (Barton et aI., 1991; Itokawa et aI., 1996; Barbier et aI., 1997; Ng et aI., 1997 ; Ito et aI., 1999; Iwata et aI., 1999; Vickery and von Zastrow, 1999) . For Dj receptors, this mechanism has been documented and visualized both in transfected cells (Trogadis et a!., 1995; Ariano et aI ., 1997; Barbier et aI., 1997) and in vivo in rat striatum (Dumartin et aI., 1998) . Intrastriatal injection of the Dj agonist SKF 82958, or intraperitoneal injection of amphetamine, changes the pattern of Dj immunoreactivity in rat striatum from a homogenous staining of plasma membranes to heteroge neous and intense cytoplasmic concentrations (Dumartin et al., 1998) . This effect is detectable as early as 4 min utes after injection.
Agonist-mediated internalization has received little at tention in the "endogenous competition" literature, with the exception of the report by Chugani et al. (1988) . These authors propose that the paradoxical response of spiperone to DA synaptic levels results from trapping of spiperone within the endocytic vesicles. They propose that DA promotes spiperone-receptor complex internal ization. The acidic environment of the vesicle results in protonization of spiperone molecules, which in turn lim its its diffusion across membranes, ensuing in an appar ently slower ko ft and increased BP. In support of their hypothesis, Chugani et al. (1988) showed that the rate of l 3 H1spiperone dissociation from microsomal membranes prepared from rat striatum following in vivo binding was fivefold slower than its dissociation following in vitro binding, and that this rate of dissociation was accelerated by mild detergent. In addition, pretreatment of rats with chloroquine, a drug that prevents receptor recycling but not internalization, significantly increased spiperone binding in the microsomal compartment. The trapping of eHJspiperone and other radioligands such as [ 3 H]ketan serin or eH]dexetimide in the endocytic compartment of intact cells has been well documented (Maloteaux et aI., 1983; Gossuin et aI., 1984) .
If such a mechanism modulates spiperone binding fol lowing changes in synaptic DA, how does it impact on benzamide binding? Agonist-induced internalization of D2 receptor differentially affects radioligand binding, de pending on the ability of the ligand to diffuse in the cells. In Y -79 human retinoblastoma cells induced to express D2 receptors, preincubation of the cells with DA pro motes a long-lasting and time-dependent increase in eH]NMSP binding and a decrease in the binding of the benzamide e the effects of DA exposure on ligand binding are ob served after washing DA out of the medium, these effects cannot be attributed to changes in occupancy of D2 re ceptors by DA. Barton et al. (199 1) propose that eH]NMSP binds to both surface-exposed and internal ized receptors, whereas [ 1 2 5 1 Jiodosulpride would bind only to surface-exposed receptors. They attribute this dif ference to the different lipophilicity of the compounds. eH]NMSP, being more lipophilic than sulpride, would access internalized receptors, whereas [ 1 2 5 lJiodosulpride would not. The authors also note that the Bmax of [ 3 H]NMSP in these cells is larger (60 fmol/mg protein) than the Bmax of [ 1 2 5 ljiodosulpride (40 fmol/mg protein). Since DA promotes internalization, the balance between internalized and exposed D2 receptors is shifted toward the internalized compartment, thereby reducing the Bmax of [ 1 2 s l]iodosulpride but not of [ 3 H]NMSP. In addition, eH]NMSP displayed higher affinity for internalized re ceptors, an observation consistent the increased in eH]NMSP binding following agonist-mediated internal ization. This observation was partially replicated in Chinese hamster ovary cells expressing the short (D2S) and long (D2L) isoforms of D2 receptors (Itokawa et aI ., 1996) . The DA exposure caused a 44% ± 3% decrease in eHJsulpride binding measured by incubation of the treated cells with eH]sulpride at 4°C for 4 hours after the DA was washed out. The half-life of the decrease in binding was estimated to be 18 ± 2 minutes, and the concentration of DA giving a half-maximal effect was estimated to be 180 ± 90 nmol/L. The binding of sulpride was restored after incubation of the cells at 37°C, indi cating that the DA-induced loss of [ 3 H]sulpride binding sites was reversible. In contrast, the binding of eHJspi perone was not affected by DA exposure under the same experimental conditions. Itokawa et al. (1996) also pro pose that the different behaviors of the ligands results from the increased lipophilicity of spiperone relative to sulpride. In other terms, agonist exposure results in a reversible sequestration of D2 receptors in a compart ment not accessible to suI pride but accessible to spiper one. Similarly, in transfected COS-7 cells, exposure fol lowed by removal of the D2 receptor agonist pergoJide does not affect eH]spiperone binding but dramatically reduces eH]sulpride binding, a result interpreted as evi dence of pergolide-induced internalization (Barbier et aI ., 1997) .
These results indicate rapid changes in cellular local ization of D2 receptors on agonist exposure, and that these changes might have a different impact on antago nist binding, dependent on the properties of the antago nist. Chugani (1988) proposes that the spiperone-D2 re ceptor complex itself is internalized, and that this inter nalization is fo llowed by a trapping of spiperone within the acidified endosomes. However, internalization of the antagonist-receptor complex has not been demonstrated for D2 receptors. In fact, it could be predicted that be cause internalization is promoted by agonist binding, the D2 receptors occupied by spiperone would be protected from internalization. However, a receptor-ligand equi librium binding state is characterized by constant disso ciation and association of the receptor-ligand complex. The formation of the agonist-receptor complex promotes internalization, followed by dissociation of this complex, resulting in a redistribution of free receptors from a membrane compartment to a endosomal compartment. It follows that the cellular redistribution of the receptors might result in apparent changes in BP of antagonists (Fig. 5) .
Thus, agonist-mediated internalization and subsequent endosomal trapping might account for both the increase in eH]spiperone binding and the decrease in eH]racIo pride binding following DA pulse if it is accepted that, like sulpride, racIopride's low lipophilicity prevents its diffusion across the plasma membranes. This proposition is directly supported by the data of Rayport and Sulzer (1995) , who measured the potency of various antipsy- The model stresses the fact that O2 receptors are distributed between a pool of receptors externalized on the plasma mem brane and a pool of receptors internalized in the endosomal corn partment. The distribution of receptors between these two com partments is dependent on agonist stimulation. Stimulation of dopamine release shifts the distribution toward the internalized compartment, whereas dopamine depletion shifts the distribution toward externalized compartment.
[' 1 C]Raclopride binds prefer entially to the externalized receptor because its relatively low lipophilicity prevents its diffusion inside the cell and because the low sodium, high proton environment of the internalized receptors decreases its affinity_ In contract, a more lipophilic ligand such as spiperone would access both externalized and internalized re ceptors. In addition, spiperone binding is less sensitive than ra clop ride binding to sodium and proton concentration, and trap ping mechanisms might provide the appearance of increased affinity of spiperone for internalized receptors , resulting in in creased spiperone accumulation after OA stimulation.
chotic drugs to affect the endosomal pH in cultured ven tral midbrain DA neurons. Because these drugs are weak bases, their accumulation within the acidic vesicles re sults in a dissipation of the pH gradient between vesicles and cytoplasm. This pH gradient can be directly visual ized with vital dye acridine orange (AO) under fluores cein epit1uorescence. Under normal conditions, the acidic milieu of the endosomes is visualized as punctate AO staining. The accumulation of the ligands in the en dosomal compartment results in dissipation of the punc tate AO staining. Table 9 lists the threshold concentra tion of various D 2 receptor antagonists at which the punctate AO staining dissipates . For example, spiperone dissipates punctate AO staining at I J.LmoIlL, whereas 1000 J.LmollL of raclopride is required to achieve the same effect. The AO threshold was well correlated with 10gP . Thus, whereas both spiperone and raclopride rap idly cross the BBB, they exhibit significant differences in their ability to cross the plasma membrane. Spiperone accesses both externalized and internalized receptor pools, whereas raclopride might not significantly access the internalized receptors. The ability of [ 1 23 I]IBZM and other benzamides to diffuse within the cell has not been evaluated. Neverthe less, the higher lipophilicity of [ ' 23 IJIBZM compared with [ " Clraclopride should enable this ligand to better diffuse within the cell, if Iipophilicity is the only factor involved in this diffusion. Since r ' 23 I1IBZM BP is af fected by DA challenges in a manner comparable to [ " Clraclopride, factors other than Iipophilicity might be involved in the ac cessibility of internalized receptors. On the other hand, the lower binding, or lack thereof, of benzamides to internalized receptors might not be just a matter of diffusion and accessibility.
For example, the binding of benzamides is dependent on the presence of sodium, whereas binding of butyro phenones such as spiperone is not sodium dependent (Stefanini et aI., 1980; Hall et aI., 1990; Lepiku et aI., 1996) . Thus, shifting the receptors from an environment with high sodium concentration (extracellular compart ment) to low sodium concentration (intracellular com partment) would result in a decrease of the affinity of raclopride and IBZM, but not of spiperone. Acidification of the receptor environment also is likely to differentially affect spiperone and raclopride binding. Spiperone bind ing is dependent on the protonization of one residue on the receptors with a pKa of 5.8, whereas raclopride is dependent on two ionizing groups with pKa of 6.7. Thus, as pH decreases during the acidification of the endo somes, raclopride affinity will be more affected than spi perone affinity (Williamson and Strange, 1990; Neve, 1991; Presland and Strange, 1991; D'Souza and Strange, 1995) . Thus, as sodium concentration decreases and pro ton concentration increases during the endocytotic pro cess, affinity of D 2 receptors for benzamides will be significantly more affected than spiperone.
The D, radiotracers tested so far behave like spiper one, that is, their binding is not reduced despite the sig nificant internalization of the D, receptor pool that fo l lows agonist challenge (Dumartin et aI., 1998) . These tracers are lipophilic and should access internalized re ceptors. Yet, like the binding of eHlraclopride, the bind ing of eH1SCH 23390 is sodium and pH dependent (Schulz et aI., 1985; Faedda et aI., 1989; Gottberg et aI., 1989; Hollis and Strange, 1992) . Thus, internalization of D, receptor in lower sodium and pH environment should decrease the affinity of SCH 23390 for D, receptors, resulting in an apparent decrease in BP. Since this is not observed, the reduced affinity from increased pH and lower sodium concentration might be compensated for by a trapping mechanism similar to the one described for spiperone.
It might be concluded that the type of experiments reviewed in this section strongly support the importance of receptor cell trafficking (internalization and recycling) in affecting radiotracer binding. However, a comprehen sive theory has not emerged, and additional work is war ranted to document the relationship between receptor cellular localization and binding of PET and SPECT ra diotracers in intact cells.
GENERAL DISCUSSION AND

UNANSWERED QUESTIONS
The occupancy model provides an adequate frame work for most observations reported with benzamides and D 2 receptor agonists such as [ 3 H1NPA. Challenges that increase synaptic DA decrease the BP of these ra diotracers, and vice versa. The amphetamine-induced re ductions of [ " C]raclopride BP and r ' 23 I]IBZM BP have been especially well validated as a measure of amphet amine-induced DA release: the amphetamine effect is mediated by DA release, since it is blunted by co- Values reproduced from Rayport and Sulzer (1995) . treatments that are expected to block amphetamine induced DA depletion (AMPT, reserpine, GBR 12909). The magnitude of the effect is proportional to the change in DA elicited in the extracellular fluids. Thus, the use of this challenge in clinical studies appears to be warranted. However, several other observations raise concerns about the general validity of the occupancy model. The simple occupancy model could still be compatible with a lack of effect of DA manipulation on spiperone binding, if it is accepted that DA has a low potency to displace spiperone from its binding site on D2 receptors, and, with the lack of effect of DA manipulation on D I receptors, if it is accepted that D I receptors are located at sites too distant from the synapse to be affected by en dogenous DA competition. At the limit, the model could survive the observation of the long-lasting effect of am phetamine on [ I I Clraclopride and [ 1 2 3 I]IBZM BP, if the hypothesis is accepted that intrasynaptic DA remains el evated for several hours fo llowing amphetamine. How ever, the simple occupancy theory is difficult to reconcile with the paradoxical behavior of butyrophenones and D I receptor ligands. These data clearly suggest that factors other than changes in DA occupancy might play a role in the modulation of receptor availability fo llowing changes in DA synaptic concentration.
The hypothesis that changes in radio ligands BP ob served in vivo following DA manipulations arc mediated by receptor internalization and its consequences for ra diotracer binding warrants further evaluation. Changes in receptor occupancy by DA are critical, since these changes will be responsible for the redistribution of the receptor pool between externalized and internalized compartments. Yet, the cellular redistribution of the re ceptor pool might be the mechanism that ultimately un derlies the observed changes in BP. Experiments in cells expressing D2 receptors demonstrate that the redistribu tion of D2 receptors between externalized and internal ized compartments could account for the opposite effects of DA agonists on raclopride and spiperone binding. This redistribution, although reversible, has a different tem poral profile than the changes in receptor occupancy fol lowing transient changes in DA concentration, which might explain the long-lasting effects of amphetamine on e I C]raclopride and [ 1 2 3 I]IBZM BP. Thus, although most observations are compatible with the classic occupancy model, the internalization model has the potential to ac count for additional observations that are difficult to rec oncile with the occupancy model. Yet, although the in ternalization model is interesting, it remains speculative, and substantive work is needed to confirm the potential importance of receptor trafficking for the phenomena described in this review.
If confirmed, this hypothesis would not necessarily invalidate the conclusions drawn from clinical studies using these challenges, since binding of DA to D2 recep-tors is the first step in the cascade of events leading to D2 receptor internalization and changes in BP. To this ex tent, these challenges still would provide a noninvasive measure of D2 receptor stimulation by DA, even if in ternalization was the mechanism underlying the ob served effect. However, as more intermediate steps are involved between the initial event (change in DA con centration) and observed outcome (reduction in BP), the more difficult becomes the interpretation of the data. For example, the exaggerated decreased in [ II CJraclopride and [ 1 2 3 I]IBZM BP observed in schizophrenic patients, a fi nding attributed to increased DA release (Laruelle et aI., 1996; Breier et aI., 1997; Abi-Dargham et aI., 1998) , might be caused by alterations in D2 receptor trafficking.
In addition, the elucidation of the exact mechanisms underlying this "benzamide effect" is important to the development of this field of brain imaging. Imaging stud ies of dynamic neurotransmission have been restricted to the study of DA transmission at the D2 receptors with substituted benzamides. Clinical results obtained with this benz amide effect highlight the promises of this tech nique for the fi eld and motivate the extension of this technique to other receptor systems. Encouraging obser vations have been reported for the muscarinic (Dewey et aI., 1990) , nicotinic (Ding et aI., 1998) and opiate sys tems (Frost, 1992) , but these observations require con siderable validation before maturing into clinical re search tools. On the other hand, results obtained so far with D 1 , DAT, and serotonin 5HT 1A ligands are disap pointing (Gatley et aI., 1995a,b; Parsey et aI., 1998; Abi Dargham et aI., 1999) . A better understanding of the multiple factors that construe radiotracer binding vulner ability to changes in endogenous transmitter levels is essential to realize the unique potential of these tech niques for measurement of synaptic transmission in the living human brain.
